(Establishment and validation of epitope-specific SARS-CoV-2 assays in blood)

The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. Within the EPI-Sars trial, we analyze and monitor immune responses towards SARS-CoV-2 in healthcare personnel in order to understand which components confer protective immunity. This includes the development of more specific analytical assays to determine protection.

This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.